Importance of clinical aspects for family physicians toward hypothyroidism assessment

Mohammed Abdulkarim M Alshehri, Alhanoof Ali Al Owaidi, Mariam Ahmed Alzahrani, Hatim ahmad m alkhudaydi, Saif Abdulrahman Alobaysi, Abdulaziz Turki Almalki, Hamdan Ahmed M Althubyani, Ahmad SalehS Alobaisy, Abdulrahman Khalaf Allah Alnemari, Mazen Hamed M Almalki, Abdullah A. Baawadh

Abstract:

Hypothyroidism commonly manifests as a slowing in physical and mental activity but may be asymptomatic. The purpose of these guidelines is to present an updated evidence-based framework for the diagnosis, treatment, and causes, symptoms of hypothyroidism. We Conducted a comprehensive computerized review of literature reporting hypothyroidism assessment in primary care by family physicians published in English language until November, 2017. The measurement of thyroid hormones in females after the age of 50, in pregnancy and after delivery, in women and men with hypercholesterolemia, in patients having had neck radiotherapy, in patients having been provided drugs, such as amiodarone and lithium, appears appropriate. Therapy is long term, generally life long and is performed by the management of thyroxine. Meanwhile, treatment of this subgroup need to be individualized by taking into consideration patient preference, presence of signs, age, and connected medical conditions.

Introduction:

Hypothyroidism is the most common disorder occurring from hormone deficiency. Inning accordance with the time of beginning it is divided in congenital and acquired, according to the degree of endocrine disorder in primary and secondary or central and inning accordance with the severity in severe or clinical and mild or subclinical hypothyroidism [1].The difference in between subclinical and clinical hypothyroidism is of major significance as in medical hypothyroidism signs are much more extreme even coma may happen, while in subclinical hypothyroidism signs and symptoms are less significant and could also be absent. The diagnosis could be conveniently executed by the measurement of blood degrees of thyroid hormones [2].Hypothyroidism is separated in primary, caused by failing of thyroid function and second (central) because of the failure of adequate thyroid-stimulating hormone (TSH) secretion from the pituitary gland or thyrotrophin-releasing hormone (TRH) from the hypothalamus. Secondary hypothyroidism can be differentiated in pituitary and hypothalamic by the use of TRH test. In some cases, failing of hormone activity in peripheral tissues can be identified. Primary hypothyroidism may be clinical, where free T4(FT4) is lowered and TSH is enhanced or subclinical where FT4 is regular and TSH is increased. In secondary hypothyroidism FT4 is lowered and TSH is regular or reduced. Primary hypothyroidism is most commonly triggered by chronic autoimmune thyroiditis, less usual causes being radioiodine therapy and thyroidectomy. Salt iodination, which is carried out consistently in many countries, could increase the occurrence of overt hypothyroidism [3].The occurrence of clinical hypothyroidism is 0.5-1.9% in women and <1% in men and of subclinical 3-13.6% in women and 0.7-5.7% in males [4].It is important to distinguish in between clinical and subclinical hypothyroidism as in clinical symptoms are major, even coma could happen, while in subclinical signs are much less and may even be lacking.

Subclinical hypothyroidism could be transformed to scientific and as current study has shown it could have various consequences, such as hyperlipidemia and boosted risk for the growth of heart disease, also heart failure, somatic and neuromuscular signs and symptoms, reproductive and various other repercussions [5].The management of novel tyrosine kinase inhibitors for the treatment of neoplastic conditions could cause hypothyroidism. Hypothyroidism is treated by the administration of thyroxine and the prognosis is excellent [6].

Hypothyroidism commonly manifests as a slowing in physical and mental activity but may be asymptomatic. The purpose of these guidelines is to present an updated evidence-based framework for the diagnosis, treatment, and causes, symptoms of hypothyroidism.

Methodology:

We Conducted a comprehensive computerized review of literature reporting hypothyroidism assessment in primary care by family physicians published in English language until November, 2017 this search was performed using electronic databases; PubMed, Medline, and Embase. Keywords used in search method were as following; “hyperthyroidism”, “Primary Care”, “Family medicine”, “assessment”, “management”.

Discussion:

- **Aetiology**

The commonest causes which are responsible for the development of primary and secondary or central hypothyroidism are shown in (Table 1) [7].

Table 1. Causes of primary and secondary (central) hypothyroidism

Primary	**Secondary**
	a.Pituitary
1.chronic autoimmune thyroiditis	1.pituitary adenomas
2.iron deficiency or excess	2.history of pituitary surgery or radiotherapy
3.thyroidectomy	3.history of head trauma
4.therapy with radioactive iodine	4.history of pituitary apoplexy
5.external radiotherapy	**b.Hypothalamus**
6.drugs	1.hypothalamic or suprasellar tumors
7.thyroid agenesis or dysgenesis	2.history of hypothalamic surgery or radiotherapy

- **Cellular and biochemical pathophysiology**

Thyroxine (T4) and triiodothyronine (T3) are produced from the thyroid gland. T4 is created only from the thyroid, whereas T3 from the thyroid and from T4 deiodination in extrathyroidal tissues. T3 deficiency is responsible for the clinical and biochemical indications of hypothyroidism. Thus, basic intracellular functions such as oxygen usage by the mitochondria and calorigenesis are slowed down. The decrease in energy metabolism and heat production is shown in the reduced basal metabolic rate, decreased appetite, cold intolerance, and slightly low basal body temperature level.

T4, which is the primary product of the thyroid and circulates in plasma, is converted to T3, T4 being in many aspects taken into consideration as a prohormone for the much more potent T3. This is executed in the cytoplasm and the nuclei of target tissue cells by 3 specific deiodinases with the subtraction of a particle of iodine from the peripheral ring of T4 [8].Deiodinases have a varied localization in tissues, varied substrates and varied practices in different medications and conditions. It is thought that the impact of T3 in target tissues is mediated genomically by T3 binding to one of the T3 receptor isoforms [9].

There is boosting evidence for non-genomic effects of T3 in addition to the transcriptional results mediated by the nuclear receptors [10].

- **Diagnosis**

The diagnosis of hypothyroidism is made from the history, the clinical picture and the laboratory measurements.

History and clinical picture

The symptoms and indications of clinical hypothyroidism are shown in Table 2 [11].The look of symptoms depends on the degree of its seriousness. This relates to the level of modification in biochemical exams. In the beginning manifestations are mild, could be distinguished with trouble from those of euthyroid patients and might be intensified with time. In a research study, only 30% of hypothyroid patients had several of the signs and symptoms, 17% of euthyroid patients contending the very least one. The assessment of symptoms is performed either when they are freshly developed, or when current aggravation of currently existing symptoms is observed. Many times the question arises regarding whether an increase in body weight is associated with hypothyroidism. This symptom needs to be evaluated under the condition that it is a tiny boost in

body weight in the order of 3 to 6 kg and not an excessive weight gain which there are other existing together symptoms. It should be kept in mind that hypothyroid people could likewise exhibit a decrease in body weight in the order of 2 to 13%. In serious hypothyroidism there are various clinical manifestations such as congestive heart failure, pericarditis, pleural effusion, intestinal obstruction and pseudo-obstruction, in addition to coagulation disorders. Neurologic indications might additionally establish such as clinical depression, psychosis, ataxia, seizures and coma. Neurocognitive deficits could likewise develop, especially in memory.

Table 2. Percentage of symptoms and signs in clinical hypothyroidism (modified) [11].

Symptoms	**(%)**	**Signs**	**(%)**
Fatique	88	Dry coarse skin	90
Cold intolerance	84	Voice hoarseness	87
Dry skin	77	Facial periorbital oedema	76
Voice hoarseness	74	Slowed movements	73
Decreased hearing	40	Mental impairment	54
Sleepiness	68	Bradycardia>60/min	90
Impaired memory	66	Bradycardia<60/min	10
Weight gain	72		
Paresthesia	56		
Constipation	52		
Hair loss	41		

In subclinical hypothyroidism most patients do not have signs and symptoms. Nevertheless, some, which approximate 30%, have [12].In a research performed in Sweden [12] 24% of patients with subclinical hypothyroidism had symptoms. As revealed the diagnosis of subclinical hypothyroidism could not be performed solely on the basis of signs and symptoms and will

certainly be performed by TSH measurement. Subclinical hypothyroidism is a danger aspect for cardiovascular disease. This boosted danger is associateded with the rise in cholesterol.

Flak et al [15] in elderly women found that subclinical hypothyroidism is a danger variable for atherosclerosis and myocardial infarction, regardless of total cholesterol degrees, high density lipoprotein, smoking and numerous other aspects. Brenta et al [14] while did not find a cholesterol boost in subclinical hypothyroidism, they discovered reduced activity of hepatic lipase and of LDL cholesterol/LDL-triglyceride ratio recommending a proatherosclerotic index. In a current study it was discovered that subclinical hypothyroidism in older adults boosts the risk of heart failure [15]. In subclinical hypothyroidism besides the cardio impacts, various disorders have been found such as conditions of nerve transmission and muscle function, disorders of the reproductive system, fertility troubles [16], increased placental detachment and premature labor [17], lowered baby birth evaluate [18] and others.

In congenital neonatal hypothyroidism hypothermia, bradycardia, jaundice, feeding unwillingness, apathy, voice hoarseness, constipation and omphalocele are generally observed. Nonetheless, in beginning there could be couple of signs and symptoms. Hence, dimension of thyroid hormones is taken into consideration required. In children growth retardation, mental retardation, voice hoarseness, constipation and either retarded or premature sexual maturation are generally observed. Medical diagnosis and management of congenital hypothyroidism need to be done with care. Kempers et al [19] measured T4, TSH and TBG in 430,764 newborn infants and found congenital long-term, permanent primary, permanent central and transient hypothyroidism in 1:2200, 1:2500, 1:21000 and 1:12000 specifically, while they had a large percentage of false positive results due to significant disorders and TBG deficiency.

Laboratory evaluation

TSH and FT4 measurement are the laboratory evaluations necessary for the medical diagnosis of hypothyroidism and the differential medical diagnosis in between primary (clinical or subclinical) and secondary one.

When TSH is enhanced and FT4 is lowered or typical hypothyroidism is primary. In this instance raised anti-TPO or anti-Tg antibodies indicate the reason for hypothyroidism, which is autoimmune thyroiditis. Primary hypothyroidism is separated in professional when TSH is boosted and FT4 is lowered and in subclinical when TSH is boosted and FT4 is typical. When TSH is normal or decreased and FT4 is reduced hypothyroidism is second (main). In order to discriminate whether the reason remains in the pituitary or the hypothalamus an examination with the TSH releasing aspect is done (TRH examination). In the first case the response is normal, while in the 2nd it is abnormal. In central hypothyroidism imaging studies of the mind and the pituitary are done aiming at locating its reason.

Normally the reported typical limitations of TSH are between 0.4-4.0 mU/l. When TSH is discovered in the upper regular restrictions it might show moderate hypothyroidism which might progress to hypothyroidism, specifically if antibodies are raised. Michalopoulou et al [20] in people with hypercholesterolemia and TSH in the middle to top normal limits found that the administration of thyroxine lowered cholesterol. Positive antithyroid antibodies predispose to the growth of hypothyroidism

TSH may be increased in euthyroid people in particular circumstances. Enhanced TSH (5-20 mU/l) is observed during convalescence from non thyroidal ailment (euthyroid unwell syndrome), also in pituitary adenomas creating TSH or in separated resistance of the pituitary to thyroid hormones. Ultimately, TSH rise could be observed in chronic kidney failing and in primary adrenal insufficiency.

- **Therapy**

Hypothyroidism treatment is done with the management of thyroxine, which is changed by 80% in peripheral cells to T3.

The day-to-day dosage of thyroxine in the initiation of alternative therapy depends upon numerous elements, such as body weight, age, the existence of coronary artery illness and cardiac arrhythmias. In grownups the dosage has to do with 1.8 µg/ kg body weight, is greater in neonates and young kids (3.8 µg/ kg) and reduced in the elderly (0.5 µg/ kg). The dose is greater in people having undergone thyroidectomy than those with chronic autoimmune thyroiditis, as in those there are remnants of working thyroid tissue. In subclinical hypothyroidism the dose is low (0.5 µg/ kg). In maternity, lastly, a bigger dosage is required (2 µg/ kg). While pregnant the boost in dosage that may be needed is 25-47% greater than the one before pregnancy and it is observed during the 4th to 6th week.

In young and healthy and balanced adults therapy could be begun with the complete dose and not necessarily with little doses. Nonetheless, in the senior or patients with coronary artery condition 25-50 µg are administered everyday and the dosage is increased by 12.5 or 25 g every 2 weeks. TSH measurement after the initiation of therapy is executed every 4-6 weeks until TSH comes to be normal. The follow-up is executed by TSH measurement as soon as every year. In pregnancy the very first TSH measurement must be carried out when maternity is diagnosed and thereafter every 3-4 weeks during the first half of the maternity and every 6 weeks after that. TSH in primary hypothyroidism on substitution therapy must be in the mean degrees to lower regular restrictions (roughly 1.0 mU/l), whereas in secondary TSH dimension does not assist. FT4and occasionally FT3 dimension is done and the values must remain in the upper fifty percent of the normal range.

In congenital hypothyroidism according to Rose et alia [21] the measurement and therapy need to be done during the very first 2 weeks of life for the avoidance of the effects of hypothyroidism. This dimension has been set up in various areas of the world, and in Greece, yet not all over. In neonates the preliminary dosage is 10-15 μg/ kg. Thereafter frequent TSH dimension is required, which must be normal and T4 or FT4, which ought to be in the top half of normal worths throughout the first 3 years of life.

In myxedema coma, which is the most extreme form of hypothyroidism and happens in long-lasting not dealt with hypothyroidism the threat of death was 60-70% in 1985 however it has lowered to 20-25%, owing to the timely medical diagnosis and the reference of patients to acute care units. Intravenous thyroxine is provided at a dose of 200-400 g during the very first 2 days and afterwards at normal doses. During the first day of therapy hydrocortisone 100 mg every 8 hours is additionally provided and hypothermia, hypoglycemia, hypotension, hyponatremia and hypercalcemia are properly treated.

Great caution is required in alternative therapy with thyroxine as dosage overestimation has consequences. It has been observed that greater than one fifth of the patients have clinical or subclinical hyperthyroidism. These effects are atrial fibrillation, aggravation of coronary artery condition and a reduction in bone mineral density, fractures of the spinal column and the hip being observed in women > 65 years [23].

Hypothyroidism is not constantly appropriately dealt with by the management of thyroxine, as there are differences in the task, security and bioavailability in between various sets of thyroxine which could also be given by the same producer. Koutras [22] commenting on the abovementioned troubles suggests the following: a) authorities ought to insist on bioavailability research studies of thyroxine preparations, b) physicians must advise their patients to take

thyroxine while fasting for a minimum of 4 hrs, and stay clear of food for a minimum of 20-30 minutes, in addition to avoid various other medications for at least 30 min after the thyroxine tablet and recognize food items or fruit juices that may interfere with thyroxine absorption, c) doctors need to not frivolously modify from one thyroxine brand name to another on the assumption that 100 µg thyroxine from brand A equals 100 µg from brand B d) physicians must report to the authorities if they have suspicious lead to several patients.

Hypothyroidism is not constantly long-term and a percentage of patients exists in whom thyroid function could be typical after thyroxine discontinuation. The normalization of thyroid function could be extra related to the antibodies to TSH receptor than to anti-TPO or anti-Tg antibodies, the titles of which little could be influenced by thyroxine management. The portion of hypothyroidism normalization after thyroxine management is in between 0-24%, imply 10%.

Conclusion:

Hypothyroidism is a frequent disease, affecting more women compared to men. The unfavorable effects of hypothyroidism, which are regular, dictate its timely medical diagnosis. Symptoms and signs of this disease are often refined and neither sensitive neither specific. Traditional symptoms and signs (eg, cold intolerance, puffiness, reduced sweating, and coarse skin) could not exist as frequently as was once believed. The measurement of thyroid hormones in females after the age of 50, in pregnancy and after delivery, in women and men with hypercholesterolemia, in patients having had neck radiotherapy, in patients having been provided drugs, such as amiodarone and lithium, appears appropriate. Therapy is long term, generally life long and is performed by the management of thyroxine. Meanwhile, treatment of this subgroup need to be individualized by

taking into consideration patient preference, presence of signs, age, and connected medical conditions.

Reference:

1. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012 Dec. 22(12):1200-35.
2. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999 Jan 11. 159(1):79-82.
3. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000 Jun 12. 160(11):1573-5.
4. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499.
5. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med. 2006;119(7):541-551
6. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001;86(10):4591-4599.
7. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev.2008February;29(1):76-131 Epub 2007 Nov 8.
8. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38–89.
9. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81:1097–1142.
10. Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol. 2008;29:211–218.
11. Georgiou E, Ntalles K, Proukakis Ch, Anousis ST. Clinical manifestations and use of microcomputer in the differential diagnosis between hypothyroid and obese women. Arch Hell Med. 1987;4:30–33.
12. Zulewski H, Mller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997;82:771–776.
13. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med. 2000;132:270–278.

14. Brenta G, Berg G, Arias P, Zago V, Schnitman M, Muzzio ML, et al. Lipoprotein alterations, hepatic lipase activity and insulin sensitivity in subclinical hypothyroidism: response to L-T(4) treatment. Thyroid. 2007;17:453–460.
15. Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health Study. J Am Coll Cardiol. 2008;52:1152–1159.
16. Abalovich M, Mitelberg L, Allami C, Gutierrez S, Alcaraz G, Otero P, et al. Subclinical hypothyroidism and thyroid autoimmunity in women with infertility. Gynecol Endocrinol. 2007;23:279–283.
17. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105:239–245.
18. Idris I, Srinivasan R, Simm A, Page RC. Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. Clin Endocrinol (Oxf) 2005;63:560–565.
19. Kempers MJ, Lanting CI, van Heijst AF, van Trotsenburg AS, Wiedijk BM, de Vijlder JJ, et al. Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls. J Clin Endocrinol Metab. 2006;91:3370–3376.
20. Michalopoulou G, Alevizaki M, Piperingos G, Mitsibounas D, Mantzos E, Adamopoulos P, et al. High serum cholesterol levels in persons with \"high-normal\" TSH levels: should one extend the definition of subclinical ypothyroidism? Eur J Endocrinol. 1998;138:141–145.
21. American Academy of Pediatrics. Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association. Brown RS, Public Health Committee. Lawson Wilkins, Pediatric Endocrine Society. Foley T, Kaplowitz PB, Kaye CL, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006;117:2290–2303.
22. Koutras DA. The treacherous use of thyroxine preparations. Stability of thyroxine preparations. Hormones. 2003;2:159–160.
23. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007May;92(5):1715-1723 Epub 2007 Feb 13.